Samsung Pharm Submits Phase III Clinical Trial Application for GV1001, a Treatment for Progressive Supranuclear Palsy

Samsung Pharm (001360) announced on June 30, 2026, that it has submitted a Phase III clinical trial application for GV1001, a treatment for progressive supranuclear palsy (PSP-RS) to the Korea Food and Drug Administration. The multi-center, double-blind, placebo-controlled, parallel-group trial will be conducted at 7-9 domestic institutions, including Borama Hospital in Seoul, and will involve 204 patients over approximately 33 months. The primary endpoint is to confirm the therapeutic efficacy of 0.56 mg GV1001 administered for 48 weeks. The company aims to provide a new treatment option for PSP-RS patients and plans to apply for product approval. Samsung Pharm's stock closed at 1,333 won, down 3.20% from the previous day. As of December 2025, the company reported total assets of 167.4 billion won, liabilities of 46.4 billion won, and net profit of 115 billion won.